Scripps Research

Previously known as The Scripps Research Institute (or TSRI), Scripps Research focuses on research and education in the biomedical sciences. Headquartered in La Jolla with a sister facility in Jupiter, Florida, Scripps is the largest private, non-profit biomedical research organization in the United States.  With a strong emphasis on studies of translational impact, Scripps Research holds nearly 1,000 patents, has produced 8 FDA-approved therapeutics, and has generated over 70 spin-off companies.

Scripps Research Mission and Goals

Scripps Research expands basic knowledge in the biosciences, and uses these fundamental advancements to develop profound innovations that improve wellbeing. Scripps researchers lead breakthrough studies that address the world’s most pressing health concerns. Through its commitment, Scripps Research is accelerating the creation and delivery of medical breakthroughs to better human health around the globe.


Scripps Research Faculty Investigators


The La Jolla campus of Scripps Research encompasses more than 1 million square feet across 35 acres on the Torrey Pines Mesa. Here, more than 160 principal investigators work with their laboratory groups to understand disease and develop effective treatments. Scripps has received a top ranking by Nature Index among all stand-alone scientific research institutes for producing high quality research and impact on innovation. Scripps infectious diseases researchers are making rapid advances in explaining how malaria, HIV, Ebola, Zika virus and other pathogens infect and attack the body, decoding how human genetics factor into a person’s ability to fight off an infection, and designing the next generation of vaccines and therapies for global health.

CHARM Collaboration Contact:  Dennis Wolan, PhD  (Associate Professor of Molecular Medicine)

CHARM ↔ Scripps Research Collaborations

CHARM and Scripps Scientists are combining expertise in assay development, medicinal chemistry, and biological assays of infectious disease therapeutics to target high priority emerging viral pathogens, multi-drug resistant bacteria, and neglected parasitic diseases with small molecule and biological drug candidates and novel vaccines. 


Lsp: A Novel Antibiotic Target

Scripps researchers developed a high-throughput screen assay for more than 600,000 compounds to discover inhibitors of the unique bacterial target, lipoprotein signal peptidase (Lsp), and then synthesized analogs to nanomolar activities. These candidates sensitized Gram-negative bacteria to membrane permeablizers, foreshadowing antibacterial agents with a novel mechanism of action against important drug-resistant bacterial pathogens.  

Read at Cell Chemical Biology